StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
6-factor scoring with sector-relative rank. Updated daily.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
Each factor shows APUS's percentile within the scored universe — observational ranking, not a recommendation.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-12 | $1.44 | $1.34 | -6.94% | 0.0M |
| 05-13 | $1.33 | $1.30 | -2.16% | 0.1M |
| 05-14 | $1.33 | $1.37 | +3.01% | 0.1M |
| 05-15 | $1.34 | $1.51 | +12.69% | 0.1M |
| 05-18 | $1.51 | $1.50 | -0.66% | 0.0M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No SEC filings available for APUS yet.
We expected SEC EDGAR XBRL data here. The issuer may file under a non-standard form, or the latest filing hasn't been parsed yet — try again later or report it via support.
Public market data, filings, and news are still available on this ticker via the other tabs.
Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of pain and inflammation associated with knee osteoarthritis. The Company operates in two segments: the biopharmaceutical segment, which is focused on the clinical development of Apitox through Lokahi, and the digital asset operations segment, which encompasses the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
No sell-side coverage available for APUS.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.